Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Amrein, K; Kachel, N; Fries, H; Hovorka, R; Pieber, TR; Plank, J; Wenger, U; Lienhardt, B; Maggiorini, M.
Glucose control in intensive care: usability, efficacy and safety of Space GlucoseControl in two medical European intensive care units.
BMC Endocr Disord. 2014; 14(8):62-62
Doi: 10.1186/1472-6823-14-62
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Amrein Karin
- Co-Autor*innen der Med Uni Graz
- Pieber Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The Space GlucoseControl system (SGC) is a nurse-driven, computer-assisted device for glycemic control combining infusion pumps with the enhanced Model Predictive Control algorithm (B. Braun, Melsungen, Germany). We aimed to investigate the performance of the SGC in medical critically ill patients. Two open clinical investigations in tertiary centers in Graz, Austria and Zurich, Switzerland were performed. Efficacy was assessed by percentage of time within the target range (4.4-8.3 mmol/L; primary end point), mean blood glucose, and sampling interval. Safety was assessed by the number of hypoglycemic episodes (≤2.2 mmol/L) and the percentage of time spent below this cutoff level. Usability was analyzed with a standardized questionnaire given to involved nursing staff after the trial. Forty medical critically ill patients (age, 62 ± 15 years; body mass index, 30.0 ± 8.9 kg/m2; APACHE II score, 24.8 ± 5.4; 27 males; 8 with diabetes) were included for a period of 6.5 ± 3.7 days (n = 20 in each center). The primary endpoint (time in target range 4.4 to 8.3 mmol/l) was reached in 88.3% ± 9.3 of the time and mean arterial blood glucose was 6.7 ± 0.4 mmol/l. The sampling interval was 2.2 ± 0.4 hours. The mean daily insulin dose was 87.2 ± 64.6 IU. The adherence to the given insulin dose advice was high (98.2%). While the percentage of time spent in a moderately hypoglycemic range (2.2 to 3.3 mmol/L) was low (0.07 ± 0.26% of the time), one severe hypoglycemic episode (<2.2 mmol/L) occurred (2.5% of patients or 0.03% of glucose readings). SGC is a safe and efficient method to control blood glucose in critically ill patients as assessed in two European medical intensive care units.
- Find related publications in this database (using NLM MeSH Indexing)
- Blood Glucose - analysis
- Critical Illness -
- Diabetes Mellitus - drug therapy
- Female -
- Follow-Up Studies -
- Humans -
- Hyperglycemia - prevention & control
- Hypoglycemia - prevention & control
- Hypoglycemic Agents - therapeutic use
- Infusions, Intravenous -
- Insulin - therapeutic use
- Intensive Care Units -
- Male -
- Middle Aged -
- Prognosis -
- Find related publications in this database (Keywords)
- Tight glycemic control
- Critical illness
- Critically ill patients
- Protocol
- Computer-assisted glycemic control
- Insulin infusion protocol
- Glucose control in intensive care